Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1991 Aug;14(4):338-45.

Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: evidence of decreased immunogenicity

Affiliations
  • PMID: 1782732
Comparative Study

Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: evidence of decreased immunogenicity

E E Adderson et al. Clin Invest Med. 1991 Aug.

Abstract

In order to assess the immunogenicity of a two-dose regimen of Haemophilus influenzae type b polysaccharide vaccine, the immune response to vaccine given at both 18 and 24 months of age was compared to the response to a single dose at 24 months of age. Following immunization at 24 months of age, the geometric mean antibody concentration of children previously immunized at 18 months (0.53 micrograms/ml) was significantly lower than that of children who received a single dose of vaccine at 24 months (1.03 micrograms/ml; p = 0.03). A four-fold rise in antibody concentration was demonstrated in 31% of children who had received two immunizations and 53% of children immunized for the first time at 24 months of age (p = 0.02). These results suggest that the administration of a dose of plain polysaccharide vaccine at 18 months of age blunted the response to reimmunization at 24 months of age. A subgroup of children who failed to respond to one or two doses of plain polysaccharide vaccine were immunized with polysaccharide-diphtheria toxoid conjugate vaccine. The majority of these children developed a significant rise in antibody concentration in response to conjugate vaccine.

PubMed Disclaimer

Similar articles

Publication types

Substances